Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
NCT ID: NCT05816642
Last Updated: 2023-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
500 participants
INTERVENTIONAL
2022-08-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
NCT06195228
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
NCT07175480
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
NCT06255223
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
NCT05524389
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05582499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single targeted therapy
sunitinib or pazopanib
sunitinib or pazopanib
Single targeted therapy
targeted therapy combined with immunotherapy
Programmed death-ligand 1 Inhibitor combined with axitinib
PD-1 inhibitor combined with axitinib
targeted therapy combined with immunotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sunitinib or pazopanib
Single targeted therapy
PD-1 inhibitor combined with axitinib
targeted therapy combined with immunotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have distant metastasis
* metastatic RCC
* Eastern Cooperative Oncology Group 0 to 1
* No obvious abnormality was found in blood routine examination, coagulation and liver and kidney function
Exclusion Criteria
* Failure to obtain baseline tumor tissue / blood samples
* A history of infection with human immunodeficiency virus, or suffer from other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation, or have a history of organ transplantation
* A history of allergy to disease treatment drugs
* During lactation or pregnancy
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
West China Hospital
OTHER
Xiangya Hospital of Central South University
OTHER
Fudan University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Second Affiliated Hospital of Nantong University
OTHER
Peking University First Hospital
OTHER
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
OTHER
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
OTHER
Zhejiang University
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
Sir Run Run Shaw Hospital
OTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
The General Hospital of Eastern Theater Command
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
The First Affiliated Hospital of University of Science and Technology of China
OTHER
The Second Hospital of Anhui Medical University
OTHER
Tongji Hospital
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Peking Union Medical College Hospital
OTHER
The First Affiliated Hospital of Shanxi Medical University
OTHER
Shaanxi Provincial Cancer Hospital
OTHER
Changzhi Medical College
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Second Affiliated Hospital of Xi'an Jiaotong University
OTHER
The First Affiliated Hospital of Air Force Medicial University
OTHER
Tang-Du Hospital
OTHER
Quanzhou First Hospital
OTHER
Third Affiliated Hospital, Sun Yat-Sen University
OTHER
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRCC-China collaboration
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.